Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra ...

A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about this latest ...

Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...

Novo Nordisk partners with Emcure Pharma to launch Poviztra (semaglutide) for weight loss in India. Expanding access to ...

With the rise of GLP-1 weight-loss injections like Ozempic and Mounjaro, many restaurant-goers report suppressed appetites ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...

Emcure becomes first Indian company to commercialise semaglutide 2.4 mg, the second brand of Wegovy®, in India.